DEA Shuts Down Four Philadelphia Pharmacies Over Record-Keeping Mess
Published Date: 4/25/2025
Notice
Summary
Four pharmacies in Philadelphia had their licenses suspended because they didn’t keep proper records of controlled substances, which could risk public safety. They didn’t ask for a hearing, so their registrations were officially revoked. This means they can’t legally handle these drugs anymore, effective immediately, impacting their business and customers.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Licenses Revoked for Four Pharmacies
Liberty Pharmacy Inc., Metro Care Pharmacy Inc., RiteCare Pharmacy Inc., and United Pharmacy Upper Darby Inc. had their DEA Certificates of Registration revoked. The revocation is effective May 27, 2025, which removes their authorization to possess or dispense controlled substances under the Controlled Substances Act.
Pending Renewal and New Registration Applications Denied
The DEA denied any pending applications by these same four pharmacies to renew or modify their registrations and denied any other pending application for additional registration in Pennsylvania. That denial is tied to the revocation effective May 27, 2025.
Documented Large Recordkeeping Discrepancies
DEA found massive discrepancies when comparing pharmacies' invoices to Pennsylvania PDMP reports, including roughly 283,400 to 300,300 dosage units of alprazolam 1 mg, roughly 554,780 to 574,320 dosage units of alprazolam 2 mg, and thousands of bottles of promethazine with codeine for each pharmacy, amounting to about a 99–100% variance in some comparisons.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-07174 — Syed Warsi, M.D.; Decision and Order
Dr. Syed Warsi from Illinois lost his medical and controlled substance licenses, so the DEA is officially revoking his registration to handle controlled substances. This means he can no longer prescribe or manage these drugs, effective immediately. If you’re a patient or partner, this change is final and means no more prescriptions from Dr. Warsi starting now.
Next: 2025-07177 — Notice of Public Meeting of the Rhode Island Advisory Committee; Correction
Heads up, Rhode Island folks! The Commission on Civil Rights fixed a mistake in their meeting notice for the Rhode Island Advisory Committee. If you planned to join or follow along, check the updated details so you don’t miss out—no money changes, just a clearer schedule.